Title Genuv Unveils GNUV205, a Bifunctional Fusion Protein That Potently Regresses Tumor Growth Without Toxicity 2022-10-13

SEOUL, Republic of Korea & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for degenerative central nervous system diseases and advanced immuno-oncology therapeutics, unveiled a new drug candidate, GNUV205, a fusion of engineered IL2 and anti-PD-1 antibody that advances immuno-oncology science. The drug candidate, for unspecified solid tumors, shows powerful anti-tumor activity without the toxicity typically associated with current IL-2 treatments.



To view original article, please click here.




Prev Targeting ‘Neurodegenerative Disease’, GENUV’s New Drug Development Strategy
Next GENUV CEO Sung-Ho Han, "To make real progress in the treatment of ALS and give hope to the patients"